{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T13:24:52Z","timestamp":1788614692073,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jpba.2021.114231","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T11:23:01Z","timestamp":1624965781000},"page":"114231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["QBD-driven HPLC method of eltrombopag olamine: Degradation pathway proposal, structure elucidation, and in silico toxicity prediction"],"prefix":"10.1016","volume":"203","author":[{"given":"Balaji","family":"Jayagopal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivashankar","family":"Murugesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2021.114231_bib0005","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2021.114231_bib0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1160\/TH07-08-0513","article-title":"Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management","volume":"99","author":"Stasi","year":"2008","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jpba.2021.114231_bib0015","doi-asserted-by":"crossref","first-page":"504","DOI":"10.4065\/79.4.504","article-title":"Management of immune thrombocytopenic Purpura in adults","volume":"79","author":"Stasi","year":"2004","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jpba.2021.114231_bib0020","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jpba.2014.04.028","article-title":"Liquid chromatography-tandem mass spectrometric assay for eltrombopag in 50\u03bcL of human plasma: A pharmacokinetic study","volume":"98","author":"Maddela","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"08","key":"10.1016\/j.jpba.2021.114231_bib0025","first-page":"8122","article-title":"Development and validation of stabilty indicating RP-HPLC method for simultaneous estimation of Eltrombopag and Romiplostim in bulk and tablet dosage form","volume":"05","author":"Begum","year":"2018","journal-title":"Indo Am. J. P. Sci"},{"key":"10.1016\/j.jpba.2021.114231_bib0030","first-page":"6097","article-title":"RP-UPLC-MS assay method for eltrombopag: application in pharmaceuticals, human plasma and urine samples","volume":"26","author":"Basha","year":"2014","journal-title":"Asian J. Chem."},{"key":"10.1016\/j.jpba.2021.114231_bib0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jpba.2013.04.027","article-title":"Critical practical aspects in the application of liquid chromatography-mass spectrometric studies for the characterization of impurities and degradation products","volume":"87","author":"Narayanam","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2021.114231_bib0040","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/chromsci\/bmw090","article-title":"QbD-driven development and validation of a HPLC method for estimation of tamoxifen citrate with improved performance","volume":"54","author":"Sandhu","year":"2016","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jpba.2021.114231_bib0045","doi-asserted-by":"crossref","first-page":"2","DOI":"10.15406\/japlr.2016.02.00039","article-title":"Implementation of quality by design approach for developing chromatographic methods with enhanced performance: a mini review","volume":"2","author":"Suman Panda","year":"2016","journal-title":"J. Anal. Pharm. Res."},{"key":"10.1016\/j.jpba.2021.114231_bib0050","doi-asserted-by":"crossref","first-page":"7087","DOI":"10.1016\/j.arabjc.2020.07.014","article-title":"QbD-mediated RP-UPLC method development invoking an FMEA-based risk assessment to estimate nintedanib degradation products and their pathways","volume":"13","author":"Jayagopal","year":"2020","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.jpba.2021.114231_bib0055","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10337-017-3393-0","article-title":"Review on implementation of multivariate approach for forced degradation study and impurity profiling with regulatory considerations","volume":"81","author":"Patel","year":"2018","journal-title":"Chromatographia"},{"key":"10.1016\/j.jpba.2021.114231_bib0060","first-page":"364","article-title":"Analytical quality by design \u2013 a legitimate paradigm for pharmaceutical analytical method development and validation","volume":"9","author":"Jayagopal","year":"2017","journal-title":"Mech Mater Sci Eng. J."},{"key":"10.1016\/j.jpba.2021.114231_bib0065","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jpba.2018.02.057","article-title":"Proposal of degradation pathway with toxicity prediction for hydrolytic and photolytic degradation products of timolol","volume":"154","author":"Devrukhakar","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2021.114231_bib0070","series-title":"Juran\u2019S Quality Control Handbook","article-title":"The quality improvement process","author":"Juran","year":"1998"},{"key":"10.1016\/j.jpba.2021.114231_bib0075","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jpba.2016.03.031","article-title":"A platform analytical quality by design (AQbD) approach for multiple UHPLC-UV and UHPLC-MS methods development for protein analysis","volume":"125","author":"Kochling","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2021.114231_bib0080","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jpha.2017.01.006","article-title":"A stability-indicating LC\u2013MS\/MS method for zidovudine: identification, characterization and toxicity prediction of two major acid degradation products","volume":"7","author":"Devrukhakar","year":"2017","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2021.114231_bib0085","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/bmc.3119","article-title":"Liquid chromatography electrospray ionization tandem mass spectrometry study of nilutamide and its stress degradation products: In silico toxicity prediction of degradation products","volume":"28","author":"Ramesh Babu","year":"2014","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2021.114231_bib0090","unstructured":"M. Sargent (Ed.), Guide to Achieving Reliable Quantitative LC-MS Measurements, RSC Analytical Methods Committee (2013) pp. 30."},{"key":"10.1016\/j.jpba.2021.114231_bib0095","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/rcm.1276","article-title":"A study of ion suppression effects in electrospray ionization from mobile phase additives and solid-phase extracts","volume":"18","author":"Mallet","year":"2004","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpba.2021.114231_bib0100","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/bmc.3613","article-title":"QbD-oriented development and validation of a bioanalytical method for nevirapine with enhanced liquid \u2013 liquid extraction and chromatographic separation","volume":"30","author":"Beg","year":"2016","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2021.114231_bib0105","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1021\/op500297g","article-title":"Quality by Design (QbD) in Action-2 : Controlling Critical Material Attributes (CMA) during the synthesis of an Active Pharmaceutical Ingredient","volume":"19","author":"Mohammed","year":"2015","journal-title":"Org. Process Res. Dev."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521003423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521003423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:17:33Z","timestamp":1760001453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708521003423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":21,"alternative-id":["S0731708521003423"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114231","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"QBD-driven HPLC method of eltrombopag olamine: Degradation pathway proposal, structure elucidation, and in silico toxicity prediction","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114231","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114231"}}